Mobile Technology for Reducing and Preventing Adolescent Suicide

减少和预防青少年自杀的移动技术

• 批准号: 10154817
• 负责人: Seth Feuerstein
• 金额: $ 39.9万
• 依托单位: OUI THERAPEUTICS, INC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-15 至 2022-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10154817
• 关键词: Adolescent; Adult; Aftercare; Age; Android; Anxiety; Apple; Caring; Cause of Death; Centers for Disease Control and Prevention (U.S.); Child; Clinical; Clinical Trials; Clinical Trials Cooperative Group; Cognitive Therapy; Data; Development; Devices; Feasibility Studies; Feedback; Feeling suicidal; Future; General Population; Goals; Heart Diseases; Hospitalization; Hospitals; Individual; Inpatients; Intervention; Life; Measures; Outcome; Participant; Patients; Phase; Population; Production; Publishing; Questionnaires; Randomized Controlled Trials; Research; Risk; Sampling; Site; Sleeplessness; Small Business Innovation Research Grant; Soldier; Suicide; Suicide attempt; Suicide prevention; Teenagers; Testing; Therapeutic; Therapy Clinical Trials; Time; United States; Visit; Work; Youth; acceptability and feasibility; adolescent suicide; age group; aged; base; cohort; commercialization; congenital anomaly; design; digital; effective intervention; effective therapy; efficacy testing; experience; feasibility testing; high risk; mobile application; mobile computing; mortality; open label; prevent; programs; reducing suicide; smartphone Application; substance use; suicidal; suicidal behavior; suicidal morbidity; suicidal risk; suicide rate; treatment as usual; trend; usability; young adult

ABSTRACT Suicide is a top two cause of death in the US for adolescents and suicide rates among youth have steadily increased. Despite this, there is a paucity of research on mobile technology designed to reduce suicide attempts among youth. In this Phase I SBIR application Oui Therapeutics, LLC proposes a project to: 1) Create a beta version of Aviva-Y for youth (ages 13 - 17); and 2) to test the feasibility and acceptability of the beta version of Aviva-Y in a single-group, open-label trial. Successful execution of the goals of this Phase I project will generate a version of Aviva-Y that is ready to be tested for efficacy with stabilized patients in a clinical trial. In the long term, this project will have a beneficial impact on the field of youth suicide prevention through the development of mobile technology designed to advance the delivery and dissemination of effective interventions.

抽象的 自杀是美国青少年的两大死因，青少年的自杀率稳步上升 增加。尽管如此，针对旨在减少自杀的移动技术的研究仍然很少 青年人之间的尝试。在此第一阶段 SBIR 应用中，Oui Therapeutics, LLC 提出了一个项目：1) 创建 面向青少年（13 - 17 岁）的 Aviva-Y 测试版； 2）测试测试版的可行性和可接受性 Aviva-Y 版本的单组、开放标签试验。顺利完成一期工程目标 将生成 Aviva-Y 的一个版本，准备在临床试验中测试稳定患者的疗效。 从长远来看，该项目将通过以下方式对青少年自杀预防领域产生有益影响： 移动技术的发展旨在促进有效的交付和传播 干预措施。